Introduction and Objective: The association between preprocedural glycemia and major adverse cardiovascular events (MACEs) and major adverse limb events (MALEs) after endovascular revascularization in diabetic patients with lower extremity arteriosclerosis obliterans (LEASO) remains unclear. The aim of this study is to explore the link between preprocedural glycaemic control and the 1-year risk of MACEs and […]
Read MoreMonth: June 2026
1267-OR: Ademaglitazone Improves Whole-Body Insulin Sensitivity while Limiting Adipogenesis and Promoting Neuroprotection in Diet-Induced Diabesity
Introduction and Objective: “Diabesity,” the coexistence of obesity and type 2 diabetes, is a major global health problem characterized by systemic insulin resistance (IR) and increased risk of neurodegenerative complications. Although thiazolidinedione (TZD) PPAR-γ agonists improve insulin sensitivity, their clinical use is limited by adverse effects including adipogenesis, weight gain, and cardiovascular risk. We developed […]
Read More1231-OR: Glucocorticoid Receptor Is Vital for Maternal β-Cell Compensation to Protect against Gestational Diabetes
Introduction and Objective: Gestational β-cell compensation is an adaptive mechanism by which maternal islets increase insulin secretion to overcome pregnancy-induced insulin resistance. Defective β-cell compensation leads to gestational diabetes mellitus (GDM). We characterized the role of glucocorticoid receptor (GR) in gestational β-cell compensation.Methods: We generated β-cell GR-knockout (βGR-KO) mice, followed by determining the abilities of […]
Read More1266-OR: Tirzepatide and Pioglitazone Combination Therapy Synergistically Improves Insulin Sensitivity and Adipose Tissue Remodeling
Introduction and Objective: Tirzepatide, a dual GLP-1 and GIP receptor agonist, enhances glucose-stimulated insulin secretion, significantly reduces HbA1c, and promotes weight loss. Tirzepatide use leads to improvements in insulin sensitivity, both via weight loss-dependent and independent mechanisms. Pioglitazone, a PPARγ activator, enhances insulin sensitivity via distinct pathways. We hypothesized that combining Tirzepatide and pioglitazone would […]
Read More1247-OR: Evolocumab Reduces CV Events in Patients with High-Risk Diabetes: Results from the VESALIUS-CV Trial
Introduction and Objective: PCSK9 inhibition with evolocumab (evo) decreased CV events in pts at high CV risk w/o a prior MI or stroke in VESALIUS-CV. This pre-specified analysis evaluates the efficacy of evo in pts w/ high-risk diabetes mellitus (HR-DM) for prevention of first CV events.Methods: VESALIUS-CV randomized pts w/ LDL-C ≥90mg/dL and atherosclerosis or […]
Read More1251-OR: Sustained Effect of a Teaching Kitchen Program for Type 2 Diabetes in Japan: Results from a Randomized Controlled Trial
Introduction and Objective: To address the unmet need for sustainable lifestyle interventions in type 2 diabetes (T2D), we evaluated the sustained effects of a Teaching Kitchen (TK) program among patients with T2D in Japan.Methods: We conducted a randomized controlled trial with 112 patients (59 men, 53 women) aged 20-79 years with T2D and BMI ≥23 […]
Read More1232-OR: Dynamic CGM Models to Predict GDM: A GO MOMs Analysis
Introduction and Objective: In GO MOMS, a multicenter observational study, % time above range (TAR) >134mg/dL, as determined from early pregnancy CGM, added statistically significant but not clinically meaningful predictive value for GDM compared to clinical factors alone. We sought to assess if prediction models incorporating CGM metrics derived from multiple time points improved GDM […]
Read More1243-OR: Novel Montelukast Derivatives for Treating Diabetic Retinopathy
Introduction and Objective: Early-stage diabetic retinopathy (DR) is characterized by vascular endothelial cell damage and breakdown of the blood-retinal barrier. We and others previously shown that CysLTR1 antagonist Montelukast (MON) is a promising treatment for diabetes-related eye issues. This study aims to develop and assess the effectiveness of new MON derivatives in alleviating endothelial dysfunction […]
Read More1239-OR: Treatment with Oxamate Improves the Counterregulatory Responses to Hypoglycemia in Diabetic Rats
Introduction and Objective: Despite advances in the development of new insulin formulations and the use of diabetes technologies, severe hypoglycemia remains a major problem for people with type 1 diabetes on intensive insulin therapy due in part to defective counterregulatory hormone responses and a lack of symptomatic awareness of hypoglycemia. Elevated brain lactate levels in […]
Read More1268-OR: Multiplexed In Vivo Screening of Visceral Adipocytes Reveals Multiple Manifestations of Insulin Sensitivity and a Novel Target to Treat Obesity
Introduction and Objective: To achieve adipose mass reduction while maintaining or improving insulin sensitivity involves an integration of multiple neuroendocrine and paracrine inputs that requires an in vivo setting to be adequately studied. We therefore performed in vivo Perturb-Seq of visceral adipocytes to identify novel targets for the treatment of obesity.Methods: An AAV library encoding […]
Read More